drugset / Trial / NCT04073147
Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase IB study investigating the pharmacokinetics of the combination venetoclax and obinutuzumab in the cerebrospinal fluid of patient with relapsed primary CNS lymphoma.
Timeline
- Start
- 2020-05-12
- Primary completion
- 2021-11-25
- Completion
- 2021-11-25
Outcome
Outcome not reported
Stopped (Enrollment): “low recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |
| Subject | Venetoclax | Small molecule | 600 mg | Oral |
| Subject | Venetoclax | Small molecule | 800 mg | Oral |
| Subject | Venetoclax | Small molecule | 1000 mg | Oral |